Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis

AIMS: Iron deficiency (ID) is a common co-morbidity in patients with heart failure (HF) and has been suggested to be associated with poor prognosis. Recently completed double-blind randomised controlled trials (RCTs) studying HF patients with ID have shown improvements in functional capacity, sympto...

ver descrição completa

Detalhes bibliográficos
Autores: Anker, Stefan D., Kirwan, Bridget-Anne, van Veldhuisen, Dirk J., Filippatos, Gerasimos, Comín Colet, Josep, Ruschitzka, Frank, Lüscher, Thomas F., rutyunov, Gregory P., Motro, Michael, Mori, Claudio, Roubert, Bernard, Pocock, Stuart J., Ponikowski, Piotr
Tipo de documento: artigo
Estado:Versão publicada
Data de publicação:2018
País:España
Recursos:Universitat Pompeu Fabra
Repositório:Repositorio Digital de la UPF
OAI Identifier:oai:repositori.upf.edu:10230/34700
Acesso em linha:http://hdl.handle.net/10230/34700
http://dx.doi.org/10.1002/ejhf.823
Access Level:Acceso aberto
Palavra-chave:Ferro -- Metabolisme
Infart
Chronic heart failure
Ferric carboxymaltose
Individual patient data meta-analysis
Iron deficiency
id ES_57c20e9f1c2f46feb31c640a20dfb0eb
oai_identifier_str oai:repositori.upf.edu:10230/34700
network_acronym_str ES
network_name_str España
repository_id_str
spelling Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysisAnker, Stefan D.Kirwan, Bridget-Annevan Veldhuisen, Dirk J.Filippatos, GerasimosComín Colet, JosepRuschitzka, FrankLüscher, Thomas F.rutyunov, Gregory P.Motro, MichaelMori, ClaudioRoubert, BernardPocock, Stuart J.Ponikowski, PiotrFerro -- MetabolismeInfartChronic heart failureFerric carboxymaltoseIndividual patient data meta-analysisIron deficiencyAIMS: Iron deficiency (ID) is a common co-morbidity in patients with heart failure (HF) and has been suggested to be associated with poor prognosis. Recently completed double-blind randomised controlled trials (RCTs) studying HF patients with ID have shown improvements in functional capacity, symptoms and quality of life when treated with i.v. ferric carboxymaltose (FCM). This individual patient data meta-analysis investigates the effect of FCM vs. placebo on recurrent hospitalisations and mortality in HF patients with ID. METHODS AND RESULTS: Individual patient data were extracted from four RCTs comparing FCM with placebo in patients with systolic HF and ID. The main outcome measures were recurrent cardiovascular (CV) hospitalisations and CV mortality. Other outcomes included cause-specific hospitalisations and death. The main analyses of recurrent events were backed up by time-to-first-event analyses. In total, 839 patients, of whom 504 were randomised to FCM, were included. Compared with those taking placebo, patients on FCM had lower rates of recurrent CV hospitalisations and CV mortality [rate ratio 0.59, 95% confidence interval (CI) 0.40-0.88; P = 0.009]. Treatment with FCM also reduced recurrent HF hospitalisations and CV mortality (rate ratio 0.53, 95% CI 0.33-0.86; P = 0.011) and recurrent CV hospitalisations and all-cause mortality (rate ratio 0.60, 95% CI 0.41-0.88; P = 0.009). Time-to-first-event analyses showed similar findings, with somewhat attenuated treatment effects. The administration of i.v. FCM was not associated with an increased risk for adverse events. CONCLUSIONS: Treatment with i.v. FCM was associated with a reduction in recurrent CV hospitalisations in systolic HF patients with ID.Wiley201820182018info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttp://hdl.handle.net/10230/34700http://dx.doi.org/10.1002/ejhf.823reponame:Repositorio Digital de la UPFinstname:Universitat Pompeu FabraInglésEuropean Journal of Heart Failure. 2018 Jan;20(1):125-33© 2017 The Authors. European Journal of Heart Failurepublished by John Wiley & Sons Ltd on behalf of European Society of Cardiology. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use anddistribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are madeinfo:eu-repo/semantics/openAccessoai:repositori.upf.edu:10230/347002026-06-12T07:21:37Z
dc.title.none.fl_str_mv Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis
title Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis
spellingShingle Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis
Anker, Stefan D.
Ferro -- Metabolisme
Infart
Chronic heart failure
Ferric carboxymaltose
Individual patient data meta-analysis
Iron deficiency
title_short Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis
title_full Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis
title_fullStr Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis
title_full_unstemmed Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis
title_sort Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis
dc.creator.none.fl_str_mv Anker, Stefan D.
Kirwan, Bridget-Anne
van Veldhuisen, Dirk J.
Filippatos, Gerasimos
Comín Colet, Josep
Ruschitzka, Frank
Lüscher, Thomas F.
rutyunov, Gregory P.
Motro, Michael
Mori, Claudio
Roubert, Bernard
Pocock, Stuart J.
Ponikowski, Piotr
author Anker, Stefan D.
author_facet Anker, Stefan D.
Kirwan, Bridget-Anne
van Veldhuisen, Dirk J.
Filippatos, Gerasimos
Comín Colet, Josep
Ruschitzka, Frank
Lüscher, Thomas F.
rutyunov, Gregory P.
Motro, Michael
Mori, Claudio
Roubert, Bernard
Pocock, Stuart J.
Ponikowski, Piotr
author_role author
author2 Kirwan, Bridget-Anne
van Veldhuisen, Dirk J.
Filippatos, Gerasimos
Comín Colet, Josep
Ruschitzka, Frank
Lüscher, Thomas F.
rutyunov, Gregory P.
Motro, Michael
Mori, Claudio
Roubert, Bernard
Pocock, Stuart J.
Ponikowski, Piotr
author2_role author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Ferro -- Metabolisme
Infart
Chronic heart failure
Ferric carboxymaltose
Individual patient data meta-analysis
Iron deficiency
topic Ferro -- Metabolisme
Infart
Chronic heart failure
Ferric carboxymaltose
Individual patient data meta-analysis
Iron deficiency
description AIMS: Iron deficiency (ID) is a common co-morbidity in patients with heart failure (HF) and has been suggested to be associated with poor prognosis. Recently completed double-blind randomised controlled trials (RCTs) studying HF patients with ID have shown improvements in functional capacity, symptoms and quality of life when treated with i.v. ferric carboxymaltose (FCM). This individual patient data meta-analysis investigates the effect of FCM vs. placebo on recurrent hospitalisations and mortality in HF patients with ID. METHODS AND RESULTS: Individual patient data were extracted from four RCTs comparing FCM with placebo in patients with systolic HF and ID. The main outcome measures were recurrent cardiovascular (CV) hospitalisations and CV mortality. Other outcomes included cause-specific hospitalisations and death. The main analyses of recurrent events were backed up by time-to-first-event analyses. In total, 839 patients, of whom 504 were randomised to FCM, were included. Compared with those taking placebo, patients on FCM had lower rates of recurrent CV hospitalisations and CV mortality [rate ratio 0.59, 95% confidence interval (CI) 0.40-0.88; P = 0.009]. Treatment with FCM also reduced recurrent HF hospitalisations and CV mortality (rate ratio 0.53, 95% CI 0.33-0.86; P = 0.011) and recurrent CV hospitalisations and all-cause mortality (rate ratio 0.60, 95% CI 0.41-0.88; P = 0.009). Time-to-first-event analyses showed similar findings, with somewhat attenuated treatment effects. The administration of i.v. FCM was not associated with an increased risk for adverse events. CONCLUSIONS: Treatment with i.v. FCM was associated with a reduction in recurrent CV hospitalisations in systolic HF patients with ID.
publishDate 2018
dc.date.none.fl_str_mv 2018
2018
2018
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10230/34700
http://dx.doi.org/10.1002/ejhf.823
url http://hdl.handle.net/10230/34700
http://dx.doi.org/10.1002/ejhf.823
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv European Journal of Heart Failure. 2018 Jan;20(1):125-33
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Wiley
publisher.none.fl_str_mv Wiley
dc.source.none.fl_str_mv reponame:Repositorio Digital de la UPF
instname:Universitat Pompeu Fabra
instname_str Universitat Pompeu Fabra
reponame_str Repositorio Digital de la UPF
collection Repositorio Digital de la UPF
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869408475536162816
score 15.198674

Registros relacionados